Effect of acyclovir nanofiber patch in treatment of recurrent herpes labialis

A novel drug delivery system using acyclovir nanofiber patch for topical treatment of recurrent herpes labialis: a randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141124020073N2

Enrollment

Registered

2020-09-03

Start date

2020-08-22

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent herpes labialis. Herpesviral vesicular dermatitis, Herpes simplex facialis, labialis

Interventions

Intervention 1: First intervention group: acyclovir nanofiber patch: Active ingredient is acyclovir in the class of antiviral drugs, main chemical composition consists of polyvinyl alcohol polymer and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recurrent (secondary) and not primary lesions Lesions in the vesicular stage (lesion size =1 cm)

Exclusion criteria

Exclusion criteria: Any allergy to acyclovir or the history of severe allergy to other drugs Diagnosis of systemic diseases; liver or kidney disorders Inherited or acquired immunodeficiency disease Manipulations, such as scratching or shaving at the site Use of birth control pills, pregnancy or lactation status Use of antiviral, anti-inflammatory, steroidal, or analgesic drugs Use of local agents, such as cosmetic products, lip lubricants, and sunscreen at the site of the lesion during treatment

Design outcomes

Primary

Measure	Time frame
Symptoms of patient discomfort (pain, itching, burning sensation). Timepoint: Daily measurement of the symptoms from the beginning of treatment (baseline) until the symptoms disappeared. Method of measurement: Using a numerical scale, ranging from 0 to 10.;Crusting time. Timepoint: Patients follow-up on the second, forth and sixth days from the baseline. Method of measurement: Clinical examination.;Healing time. Timepoint: Patients follow-up on the second, forth and sixth days from the baseline. Method of measurement: Clinical examination.	—

Measure

Time frame

Symptoms of patient discomfort (pain, itching, burning sensation). Timepoint: Daily measurement of the symptoms from the beginning of treatment (baseline) until the symptoms disappeared. Method of measurement: Using a numerical scale, ranging from 0 to 10.;Crusting time. Timepoint: Patients follow-up on the second, forth and sixth days from the baseline. Method of measurement: Clinical examination.;Healing time. Timepoint: Patients follow-up on the second, forth and sixth days from the baseline. Method of measurement: Clinical examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Golestannejad

Esfahan University of Medical Sciences

golestannejad@dnt.mui.ac.ir+98 31 3792 5515

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 13, 2026